<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02271204</url>
  </required_header>
  <id_info>
    <org_study_id>ML21741</org_study_id>
    <nct_id>NCT02271204</nct_id>
  </id_info>
  <brief_title>Observational Study of iv Ibandronate in Women With Postmenopausal Osteoporosis</brief_title>
  <official_title>Post Authorization Safety Study of iv Ibandronate (Bonviva) in Postmenopausal Osteoporosis, Observational, Non-interventional Open Label Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clinic of Endocrinology and Metabolic Disorders, Macedonia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinic for Orthopedic Surgery, Skopje</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital, Kumanovo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>General Hospital, Struga</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Faculty, Institute for Epidemiology and Biostatistics, Skopje</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Clinic of Endocrinology and Metabolic Disorders, Macedonia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This observational study assess the safety of intravenous Ibandronate (Bonviva) intermittent
      administration in patients with postmenopausal osteoporosis and the efficacy of IV
      Ibandronate (Bonviva treatment through relative lumbar spine and hip bone mineral
      densitometry form baseline at year 1)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2009</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Adverse Events and Serious Adverse Events as a Measure of Safety and Tolerability of intravenous Ibandronate intermittent administration in patients with postmenopausal osteoporosis</measure>
    <time_frame>end of observation 12 months</time_frame>
  </primary_outcome>
  <enrollment type="Actual">700</enrollment>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibandronic acid</intervention_name>
    <description>As prescribed by physician</description>
    <other_name>Bonviva</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women with postmenopausal osteoporosis in everyday routine practice from selected centers
        in R. Macedonia
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients had post menopausal osteoporosis

          -  Patients had no contraindication for bisphosphonates

          -  Patients had been naive for ibandronate therapy

          -  Patients who have signed informed consent and are willing to share their data for data
             analysis

        Exclusion Criteria:

          -  Is not Ibandronate na√Øve

          -  Hypersensitivity to any component of the bisphosphonates Ibandronate;

          -  Administration of any investigational drug within 30 days preceding the first dose of
             the study drug.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2014</study_first_submitted>
  <study_first_submitted_qc>October 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2014</study_first_posted>
  <last_update_submitted>October 20, 2014</last_update_submitted>
  <last_update_submitted_qc>October 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Osteoporosis, Postmenopausal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibandronic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

